anti- braf v600e mouse monoclonal antibody clone ve1  (Spring Bioscience)

Journal: Cancers

Article Title: Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAF V600E Mutation in Thyroid Cancer

doi: 10.3390/cancers15133449

Figure Lengend Snippet: Correlations between PD-L1 expression and clinicopathological factors in thyroid cancer.

Article Snippet: IHC was carried out using the following primary antibodies: an anti PD-L1 (clone E1L3N; 1/200; Cell Signaling Technology, Inc., (CST), Danvers, MA, USA), anti BRAF V600E (clone VE1; 1/500; Spring Bioscience, Pleasanton, CA, USA), and anti CD8 (clone 4B11; ready to use; Leica BIOSYSTEMS Ltd., Newcastle, UK).

Techniques: Expressing, Mutagenesis

Journal: Cancers

Article Title: Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAF V600E Mutation in Thyroid Cancer

doi: 10.3390/cancers15133449

Figure Lengend Snippet: Univariate analysis of clinicopathological factors associated with PFS.

Article Snippet: IHC was carried out using the following primary antibodies: an anti PD-L1 (clone E1L3N; 1/200; Cell Signaling Technology, Inc., (CST), Danvers, MA, USA), anti BRAF V600E (clone VE1; 1/500; Spring Bioscience, Pleasanton, CA, USA), and anti CD8 (clone 4B11; ready to use; Leica BIOSYSTEMS Ltd., Newcastle, UK).

Techniques: Mutagenesis

Journal: Cancers

Article Title: Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAF V600E Mutation in Thyroid Cancer

doi: 10.3390/cancers15133449

Figure Lengend Snippet: Multivariate analysis of clinicopathological factors associated with PFS.

Article Snippet: IHC was carried out using the following primary antibodies: an anti PD-L1 (clone E1L3N; 1/200; Cell Signaling Technology, Inc., (CST), Danvers, MA, USA), anti BRAF V600E (clone VE1; 1/500; Spring Bioscience, Pleasanton, CA, USA), and anti CD8 (clone 4B11; ready to use; Leica BIOSYSTEMS Ltd., Newcastle, UK).

Techniques: Mutagenesis

Journal: Cancers

Article Title: Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAF V600E Mutation in Thyroid Cancer

doi: 10.3390/cancers15133449

Figure Lengend Snippet: Kaplan–Meier curves for PFS; ( a ) with negative or positive PD-L1 expression, ( b ) with BRAF V600E mutation or wild type, and ( c ) with negative or positive CD8+ expression. *: statistically significant.

Article Snippet: IHC was carried out using the following primary antibodies: an anti PD-L1 (clone E1L3N; 1/200; Cell Signaling Technology, Inc., (CST), Danvers, MA, USA), anti BRAF V600E (clone VE1; 1/500; Spring Bioscience, Pleasanton, CA, USA), and anti CD8 (clone 4B11; ready to use; Leica BIOSYSTEMS Ltd., Newcastle, UK).

Techniques: Expressing, Mutagenesis

Journal: Medicina

Article Title: Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

doi: 10.3390/medicina57111246

Figure Lengend Snippet: Summary of clinicopathological and immunohistochemical features in case groups.

Article Snippet: The following primary monoclonal antibodies were used: CD56 antibody (clone RCD56; Zytomed, Berlin, Germany), CK19 antibody (clone B170; Leica, Newcastle, UK), HBME-1 antibody (clone HBME-1; Genemed, South San Francisco, CA, USA), galectin-3 antibody (clone 9C4; Leica, Bannockburn, IL, USA), CITED1 (clone CITED-1; Abcam, Cambridge, UK), TROP-2 antibody (clone F-5; Santa Cruz Biotechnology, Dallas, TX, USA), and anti- BRAF V600E (VE1) antibody (clone VE1; Spring Bioscience, Pleasanton, CA, USA).

Techniques: Immunohistochemical staining

Journal: Medicina

Article Title: Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

doi: 10.3390/medicina57111246

Figure Lengend Snippet: Representative microscopic findings for expression of the seven markers in benign follicular nodules and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). ( a ) Hematoxylin–eosin (HE) stain for a Hürthle cell adenoma; ( b ) CD56 showed diffuse and complete membrane staining; ( c ) CK (cytokeratin) 19 and ( d ) HBME-1 showed no expression; ( e ) galectin-3 showed focal cytoplasmic staining; ( f ) CITED1 showed diffuse cytoplasmic and nuclear staining; ( g ) VE1 showed negative staining; ( h ) TROP-2 showed focal staining, but the majority of follicular adenomas showed negative staining; ( i ) HE stain for a NIFTP; ( j ) CD56 showed diffuse staining; ( k ) CK19 showed diffuse staining; ( l ) HBME-1 showed negative staining in this case but more than half of the NIFTPs showed positive results; ( m ) galectin-3 showed negative staining; ( n ) CITED1 showed focal cytoplasmic and nuclear staining in this case, consistent with a negative result. Most NIFTP cases, however, showed positive results; ( o ) VE1 and ( p ) TROP-2 showed no expression (original magnification, 200×).

Article Snippet: The following primary monoclonal antibodies were used: CD56 antibody (clone RCD56; Zytomed, Berlin, Germany), CK19 antibody (clone B170; Leica, Newcastle, UK), HBME-1 antibody (clone HBME-1; Genemed, South San Francisco, CA, USA), galectin-3 antibody (clone 9C4; Leica, Bannockburn, IL, USA), CITED1 (clone CITED-1; Abcam, Cambridge, UK), TROP-2 antibody (clone F-5; Santa Cruz Biotechnology, Dallas, TX, USA), and anti- BRAF V600E (VE1) antibody (clone VE1; Spring Bioscience, Pleasanton, CA, USA).

Techniques: Expressing, H&E Stain, Membrane, Staining, Negative Staining

Journal: Medicina

Article Title: Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

doi: 10.3390/medicina57111246

Figure Lengend Snippet: Representative microscopic findings for expression of the seven markers in noninvasive encapsulated follicular variants of papillary thyroid carcinomas (NEFVPTCs) and infiltrative follicular variants of papillary thyroid carcinomas (IFVPTCs). ( a ) HE stain for a NEFVPTC; ( b ) CD56 showed diffuse membrane staining; ( c ) CK19 showed focal cytoplasmic staining; ( d ) HBME-1 showed negative staining in this case, but more than half of the NEFVPTCs showed positive results; ( e ) galectin-3 showed negative staining; ( f ) CITED1 showed diffuse cytoplasmic and nuclear staining; ( g ) VE1 and ( h ) TROP-2 showed results of negative staining; ( i ) HE stain for an IFVPTC; ( j ) CD56 showed loss of expression; ( k ) CK19 showed diffuse cytoplasmic and membrane staining; ( l ) HBME-1 showed diffuse membrane staining; ( m ) galectin-3 showed diffuse cytoplasmic staining; ( n ) CITED1 showed diffuse cytoplasmic and nuclear staining; ( o ) VE1 showed homogenous cytoplasmic staining; ( p ) TROP-2 showed diffuse membrane staining (original magnification, 200×).

Article Snippet: The following primary monoclonal antibodies were used: CD56 antibody (clone RCD56; Zytomed, Berlin, Germany), CK19 antibody (clone B170; Leica, Newcastle, UK), HBME-1 antibody (clone HBME-1; Genemed, South San Francisco, CA, USA), galectin-3 antibody (clone 9C4; Leica, Bannockburn, IL, USA), CITED1 (clone CITED-1; Abcam, Cambridge, UK), TROP-2 antibody (clone F-5; Santa Cruz Biotechnology, Dallas, TX, USA), and anti- BRAF V600E (VE1) antibody (clone VE1; Spring Bioscience, Pleasanton, CA, USA).

Techniques: Expressing, H&E Stain, Membrane, Staining, Negative Staining

Journal: Medicina

Article Title: Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

doi: 10.3390/medicina57111246

Figure Lengend Snippet: The comparison for expression of seven immunohistochemical markers among different thyroid lesions.

Article Snippet: The following primary monoclonal antibodies were used: CD56 antibody (clone RCD56; Zytomed, Berlin, Germany), CK19 antibody (clone B170; Leica, Newcastle, UK), HBME-1 antibody (clone HBME-1; Genemed, South San Francisco, CA, USA), galectin-3 antibody (clone 9C4; Leica, Bannockburn, IL, USA), CITED1 (clone CITED-1; Abcam, Cambridge, UK), TROP-2 antibody (clone F-5; Santa Cruz Biotechnology, Dallas, TX, USA), and anti- BRAF V600E (VE1) antibody (clone VE1; Spring Bioscience, Pleasanton, CA, USA).

Techniques: Comparison, Expressing, Immunohistochemical staining

Journal: Medicina

Article Title: Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

doi: 10.3390/medicina57111246

Figure Lengend Snippet: The significance of the seven IHC markers, alone and in combinations, in BFN versus IFVPTC.

Article Snippet: The following primary monoclonal antibodies were used: CD56 antibody (clone RCD56; Zytomed, Berlin, Germany), CK19 antibody (clone B170; Leica, Newcastle, UK), HBME-1 antibody (clone HBME-1; Genemed, South San Francisco, CA, USA), galectin-3 antibody (clone 9C4; Leica, Bannockburn, IL, USA), CITED1 (clone CITED-1; Abcam, Cambridge, UK), TROP-2 antibody (clone F-5; Santa Cruz Biotechnology, Dallas, TX, USA), and anti- BRAF V600E (VE1) antibody (clone VE1; Spring Bioscience, Pleasanton, CA, USA).

Techniques:

Journal: Medicina

Article Title: Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions

doi: 10.3390/medicina57111246

Figure Lengend Snippet: The significance of the six markers, alone and in combinations, in NIFTP/NEFVPTC versus IFVPTC.

Article Snippet: The following primary monoclonal antibodies were used: CD56 antibody (clone RCD56; Zytomed, Berlin, Germany), CK19 antibody (clone B170; Leica, Newcastle, UK), HBME-1 antibody (clone HBME-1; Genemed, South San Francisco, CA, USA), galectin-3 antibody (clone 9C4; Leica, Bannockburn, IL, USA), CITED1 (clone CITED-1; Abcam, Cambridge, UK), TROP-2 antibody (clone F-5; Santa Cruz Biotechnology, Dallas, TX, USA), and anti- BRAF V600E (VE1) antibody (clone VE1; Spring Bioscience, Pleasanton, CA, USA).

Techniques:

Journal: Annals of Surgical Oncology

Article Title: Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

doi: 10.1245/s10434-020-08713-1

Figure Lengend Snippet: Lymphocyte biomarkers and distribution by BRAF mutation status

Article Snippet: For BRAF V600E IHC, Pleasanton, CA Spring Bioscience mouse anti-human BRAF V600E monoclonal antibody (Clone VE1) was used at a dilution of 1:200 run on a routine long program.

Techniques: Mutagenesis

Journal: Annals of Surgical Oncology

Article Title: Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

doi: 10.1245/s10434-020-08713-1

Figure Lengend Snippet: Clinical response to DPCP correlated with OS by biomarker status

Article Snippet: For BRAF V600E IHC, Pleasanton, CA Spring Bioscience mouse anti-human BRAF V600E monoclonal antibody (Clone VE1) was used at a dilution of 1:200 run on a routine long program.

Techniques: Biomarker Discovery

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: Papillary thyroid carcinoma, classic type (a) showing diffuse cytoplasmic VE1 expression with moderate intensity (b); Papillary thyroid carcinoma, invasive follicular variant (c) showing negative VE1 immunostain (d). Evaluation of VE1 immunostain in papillary thyroid carcinoma at low power (e) may be deceptive. Higher power examination confirms diffuse but weak VE1 positivity (f) in a case with confirmed BRAF V600E mutation by next generation sequencing (unpublished data). These examples utilized prediluted Roche Ventana VE1 monoclonal antibody (Indianapolis, IN, USA) on the Leica Bond Refine System (Buffalo Grove, IL, USA) at 60 min incubation time

Article Snippet: The majority of the studies used the anti-human BRAF V600E (clone VE1) monoclonal antibody by Spring Bioscience (Spring Bioscience Pleasanton, CA, USA) [ 11 , 13 – 15 , 18 , 21 , 25 , 26 , 28 – 30 , 32 , 39 , 40 ] or Ventana medical systems (Ventana Medical Systems, Roche Diagnostics Indianapolis, IN, USA) [ 12 , 17 , 19 , 20 , 22 , 33 – 35 ].

Techniques: Expressing, Variant Assay, Mutagenesis, Next-Generation Sequencing, Incubation